{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:21:45Z","timestamp":1761016905961},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.euroneuro.2011.06.002","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T17:47:08Z","timestamp":1309974428000},"page":"92-99","source":"Crossref","is-referenced-by-count":6,"title":["Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study"],"prefix":"10.1016","volume":"22","author":[{"given":"V.","family":"Parks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.W.","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Plotka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2011.06.002_bb0005","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0924-977X(01)00101-8","article-title":"Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram","volume":"11","author":"Brosen","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2011.06.002_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1358\/dof.2007.032.05.1092901","article-title":"Lecozotan hydrochloride","volume":"32","author":"Childers","year":"2007","journal-title":"Drugs Future"},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0009-9236(98)90035-2","article-title":"Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of the development of the \u201cserotonin syndrome\u201d","volume":"63","author":"Dingemans","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0025","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.euroneuro.2011.06.002_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/026988119901300111","article-title":"The serotonin syndrome and its treatment","volume":"13","author":"Gillman","year":"1999","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.euroneuro.2011.06.002_bb0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1592\/phco.20.19.1441.34851","article-title":"Steady-state pharmacokinetics of citalopram in young and elderly subjects","volume":"20","author":"Gutierrez","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01874.x","article-title":"Metabolism of citalopram enantiomers in CYP2C19\/CYP2D6 phenotyped panels of healthy Swedes","volume":"56","author":"Herrlin","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2011.06.002_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/CLT-120037428","article-title":"Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose","volume":"42","author":"Isbister","year":"2004","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0050","first-page":"361","article-title":"Serotonin toxicity: a practical approach to diagnosis and treatment","volume":"187","author":"Isbister","year":"2007","journal-title":"MJA"},{"issue":"5","key":"10.1016\/j.euroneuro.2011.06.002_bb0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.pra.0000336754.19566.65","article-title":"An open pilot study of the combination of escitalopram and buproprion-SR for outpatients with major depressive disorder","volume":"14","author":"Leuchter","year":"2008","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.psyneuen.2005.11.005","article-title":"L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI","volume":"31","author":"Lowe","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005792-200007000-00001","article-title":"Serotonin syndrome. Presentation of 2 cases and review of the literature","volume":"79","author":"Mason","year":"2000","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.06.002_bb0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2125.2008.03348.x","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects","volume":"67","author":"Patat","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0075","author":"Plotka","year":"2008"},{"issue":"1","key":"10.1016\/j.euroneuro.2011.06.002_bb0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.clpt.6100232","article-title":"A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease","volume":"83","author":"Raje","year":"2008","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0085","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1124\/jpet.105.086363","article-title":"Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties","volume":"314","author":"Schechter","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hup.672","article-title":"Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression","volume":"20","author":"Segrave","year":"2005","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.06.002_bb0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pbb.2006.07.013","article-title":"Pindolol does not augment central serotonin function increases to citalopram in humans: an auditory evoked potential investigation","volume":"85","author":"Segrave","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"10","key":"10.1016\/j.euroneuro.2011.06.002_bb0100","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/dmd.31.10.1255","article-title":"Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19","volume":"31","author":"Yu","year":"2003","journal-title":"Drug Metab. Dispos."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T17:21:12Z","timestamp":1543684872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X11001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0924977X11001313"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.06.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}